Robert M. Curtis

Director

Allan W. May

Chairman

Casey J. McGlynn

Investor

85 past transactions

Embolx

Seed Round in 2019
Embolx is a venture-backed start-up in Silicon Valley developing and commercializing unique catheter-based systems that enable a breakthrough in minimally invasive localized cancer therapy. Embolx devices use pressure regulation to eliminate non-target delivery and increase drug distribution in the tumor using an advanced method known as Low Pressure Embolization (LPE).

InvVax

Venture Round in 2017
InvVax, Inc. develops and commercializes influenza vaccine that prevents pandemics. It focuses on identifying influenza vaccines for HIV, Hepatitis B, and Hepatitis C. The company was founded in 2012 and is based in Los Angeles, California.

BioTrace Medical

Venture Round in 2020
BioTrace Medical is dedicated to reinventing temporary pacing to improve patient outcomes and reduce hospital costs. BioTrace Medical is a stealth-stage company focused on the production of medical devices. The company was founded by Aravind Swaminathan and Ellis Garai in 2013 and is based in San Mateo, California.

Astrocyte Pharmaceuticals

Series A in 2021
Astrocyte Pharmaceuticals Inc., a small drug development company, develops neuroprotection therapies for traumatic brain injuries (TBI), concussions, acute ischemic stroke, neurodegenerative disorders, and other injuries to the brain. It offers AST-004, a novel small molecule for acute administration of patients that protects and repairs neurons that are damaged by selectively stimulating astrocytes. Astrocyte Pharmaceuticals Inc. was incorporated in 2014 and is based in Cambridge, Massachusetts.

InvVax

Venture Round in 2018
InvVax, Inc. develops and commercializes influenza vaccine that prevents pandemics. It focuses on identifying influenza vaccines for HIV, Hepatitis B, and Hepatitis C. The company was founded in 2012 and is based in Los Angeles, California.

TransformativeMed

Venture Round in 2019
TransformativeMed, Inc. develops and delivers software solutions for hospitals and health application partners. The company offers Smart Health Apps, which are healthcare applications that integrate with EMR data, user-interface, and physician workflow leveraging the MPages development toolkit. Its solutions include CORES Smart Handoffs, a one-click sign-out solution for providers to sign out their patient lists to incoming providers; GlycemiCare Smart Glucose, which enables inpatient healthcare teams to practice glycemic control transitions to improve patient safety and reduces complications; and ACR Select Smart Imaging that integrates into the EMR with imaging decision support functions performed at the point of order entry. The company was founded in 2007 and is headquartered in Seattle, Washington.

Embolx

Venture Round in 2016
Embolx is a venture-backed start-up in Silicon Valley developing and commercializing unique catheter-based systems that enable a breakthrough in minimally invasive localized cancer therapy. Embolx devices use pressure regulation to eliminate non-target delivery and increase drug distribution in the tumor using an advanced method known as Low Pressure Embolization (LPE).

TeVido BioDevices

Venture Round in 2019
TeVido BioDevices, Inc, a biotech start-up, develops tissue engineered products for reconstructive surgery. It operates a platform technology that uses 3D bio-printing and a patient’s living cells to build custom grafts that address unmet needs in the field of reconstructive and cosmetic surgery. The company was incorporated in 2016 and is based in Austin, Texas.

Stimwave LLC

Venture Round in 2020
Stimwave Technologies, Inc., a medical device company, engages in the development, manufacture, commercialization, and marketing of wireless microsize injectable medical devices for neurology markets. The company was formerly known as Neural Micro Incorporated. Stimwave Technologies, Inc. was incorporated in 2010 and is based in Scottsdale, Arizona.

S2 Genomics

Venture Round in 2019
S2 Genomics, Inc. develops integrated sample preparation systems that processes tissues and liquid samples into genomic samples. The company also provides spatial sequencing technology that captures three dimensional coordinates of single cells in tissue for NGS readout. S2 Genomics, Inc. was founded in 2016 and is based in Livermore, California.

Nanostim

Venture Round in 2013
Nanostim is an early-stage medical device company working to prevent more than 100,000 annual complications related to pacemakers. Nanostim has assembled a world-class team of experienced medical device engineers to help bring this exciting technology to the marketplace.

Breathe Technologies

Series B in 2008
Breathe Technologies, Inc was founded in 2005 with the objective of empowering healthcare providers and patients with new, reliable and accessible respiratory therapies that optimize breathing and mobility. They are in the process of developing truly ultra-light, compact, patient-friendly ventilator systems that can transform respiratory care in the hospital and home markets.

NSpine

Series A in 2005
NSpine, Inc. engages in designing and developing devices for stabilization and motion preservation of the lumbar spine via minimally invasive surgery. Its product includes NFlex, a titanium pedicle screw system, which provides support to the spinal motion segment and also used in non-fusion/hybrid applications.

Strategikon

Seed Round in 2020
Strategikon Pharma, Inc. designs and develops a software that synchronizes sponsor and provider outsourcing processes. It offers Clinical Maestro, a transaction room that uses collaborative technology infrastructure and standardized bid grid language to create a shared virtual transaction environment. The company's software is also used for clinical financial management, vendor performance metrics management, portfolio analytics, CRO and clinical vendor oversight, clinical outsourcing, and contract lifecycle management. In addition, it offers consulting services to newly established clinical business operations. Strategikon Pharma, Inc. was founded in 2016 and is based in San Rafael, California.

VasoNova

Series A in 2007
VasoNova, Inc. manufactures and markets medical devices. It develops a self-guided PICC catheter. The company is based in Sunnyvale, California.

OncoHealth

Series A in 2011
OncoHealth designs screening devices that detects and diagnoses cancer. Its devices focus on the development of protein bio-markers for screening and diagnostics of cervical cancer and other HPV-associated cancers, enabling medical professionals to monitor, diagnose, and treat cancer.

Verdezyne

Series C in 2007
Verdezyne was a privately-held company that employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercial fermentation processes for the production of petrochemical replacements.

Anubis Bio

Seed Round in 2020
Anubis Bio Corporation, a medical nutrition company, develops and manufactures products to control diarrhea in dogs and cats. It offers DoggyStat, a products that provides symptomatic relief and eliminates diarrhea causing infections in dogs and cats. Anubis Bio Corporation was incorporated in 2018 and is based in Orlando, Florida.

Seal Rock Therapeutics

Seed Round in 2017
Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.

Zogenix

Series A in 2006
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Saccharo

Venture Round in 2021
Saccharo is a biotech start-up in the immuno-oncology space that develops therapeutic products for the treatment of cancer and other novel diseases. Saccharo discovered a polysaccharide that surrounds human cancer cells. The Sacchario approach has a mechanism of action that allows drugs to have multiple killing effects, a predicted safety profile, a broad therapeutic window, and applications to many cancers.

Nanotech Biomachines

Venture Round in 2014
Nanotech Biomachines develops a sensor technology for therapeutic discovery and development applications.

Inhalon Biopharma

Seed Round in 2020
Inhalon Biopharma, Inc. develops monoclonal antibodies that enables trapping of pathogens in mucus secretions for the treatment and prevention of respiratory infections. The company’s product is used for the treatment and prevention of respiratory syncytial virus (RSV), which causes infections of the lungs and respiratory tract in Children. The company was founded in 2018 and is based in Carrboro, North Carolina.

Pegasus Biologics

Series B in 2005
Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.

Verdezyne

Series B in 2006
Verdezyne was a privately-held company that employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercial fermentation processes for the production of petrochemical replacements.

Altheos

Series A in 2010
Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Trak

Angel Round in 2014
Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone’s lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by Ph.D. scientists developing medical technologies for national defense applications at Sandia National Laboratories.

Chameleon Biosciences

Seed Round in 2019
Chameleon Biosciences Inc. develops Adeno Associated Virus (AAV) based gene therapy to treat rare diseases. The company offers AAV based products that deliver therapeutic proteins to specific tissues while reducing antigen specific immune responses to both the vector and the therapeutic protein for increased gene delivery, reduced immunogenicity, and broader applications with the aim of treating patients suffering from rare diseases. The company was founded in 2017 and is headquartered in San Anselmo, California.

Gemmus Pharma

Series B in 2014
Gemmus Pharma is a drug development company founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.

OncoHealth

Angel Round in 2011
OncoHealth designs screening devices that detects and diagnoses cancer. Its devices focus on the development of protein bio-markers for screening and diagnostics of cervical cancer and other HPV-associated cancers, enabling medical professionals to monitor, diagnose, and treat cancer.

Zephyrus Biosciences

Seed Round in 2014
Zephyrus Biosciences provides research tools to enable protein analysis at the single-cell level. Addressing the burgeoning single-cell analysis market, our first product, the scWestern system, enables western blotting on individual cells for the first time. Researchers will utilize Zephyrus’s products to gain new insights into the biology of cancer, stem cells, neurology, and human disease and development. It was founded in 2013 and headquartered in Berkeley, California.

Vaxart

Series A in 2007
Vaxart is a privately held biotechnology company near UCSF Mission Bay in San Francisco. Their mission is to develop rapid and efficient vaccine technology to fight infectious diseases. Vaxart was founded in 2004 and has filed patents covering its novel platform technology for vaccination using vectors together with TLR ligands.

Vaxart

Series B in 2010
Vaxart is a privately held biotechnology company near UCSF Mission Bay in San Francisco. Their mission is to develop rapid and efficient vaccine technology to fight infectious diseases. Vaxart was founded in 2004 and has filed patents covering its novel platform technology for vaccination using vectors together with TLR ligands.

VALFIX Medical

Private Placement in 2019
VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.

Verdezyne

Venture Round in 2009
Verdezyne was a privately-held company that employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercial fermentation processes for the production of petrochemical replacements.

Velomedix

Series A in 2009
Velomedix, Inc. is a therapeutic hypothermia company in the United States. Its therapeutic hypothermia technology offers a novel solution for the protection of the body's organs during ischemic or inflammatory insults. Velomedix, Inc. is based in Menlo Park, California.

Allylix

Venture Round in 2007
Allylix, Inc., an early stage biotechnology company, develops terpene products and their derivatives for the flavor and fragrance, food ingredient, pharmaceutical, agricultural, and biofuel markets. Its products comprise nootkatone, which is a grapefruit flavor that is used in fruit juices and citrus flavored sodas. The company also develops sesquiterpenes that are part of aroma chemical segment of the flavor and fragrance market; and production platforms for pharmaceutical, nutraceutical, and agricultural markets. Allylix, Inc. was founded in 2002 and is based in San Diego, California with research and development laboratories in Lexington, Kentucky.

Retrotope

Series B in 2015
Retrotope Inc. develops drugs for the treatment of degenerative and intractable diseases. The company develops drugs for the treatment of diseases, such as Parkinson, Alzheimer, mitochondrial myopathies, and retinopathies. It provides RT001, a drug for the treatment of infantile neuroaxonal dystrophy. It also operates an online drug platform to preserve and restore mitochondrial health in degenerative diseases. Retrotope Inc. was incorporated in 2006 and is based in Los Altos, California.

Nanotech Biomachines

Seed Round in 2017
Nanotech Biomachines develops a sensor technology for therapeutic discovery and development applications.

nVision Medical

Series A in 2013
NVISION MEDICAL Corporation operates in the healthcare sector. The company was incorporated in 2009 and is based in Saratoga, California. nVision is a privately-held medical device company dedicated to filling the void in women’s health innovation. Since its founding in 2011, the company has relentlessly focused on developing devices to enable clinicians to assess the health of previously inaccessible parts of the female reproductive tract.

Neurava

Seed Round in 2024
Neurava is working to develop a first of its kind, wearable diagnostic for epilepsy patients, including those at risk of SUDEP.

Astrocyte Pharmaceuticals

Series B in 2023
Astrocyte Pharmaceuticals Inc., a small drug development company, develops neuroprotection therapies for traumatic brain injuries (TBI), concussions, acute ischemic stroke, neurodegenerative disorders, and other injuries to the brain. It offers AST-004, a novel small molecule for acute administration of patients that protects and repairs neurons that are damaged by selectively stimulating astrocytes. Astrocyte Pharmaceuticals Inc. was incorporated in 2014 and is based in Cambridge, Massachusetts.

Avisi Technologies

Seed Round in 2022
Avisi Technologies develops a nanotechnology-enabled defense against blindness from glaucoma. Avisi's product, VisiPlate, is a next-generation aqueous shunt that aims to treat mid to late-stage glaucoma. It is 20x thinner than a human hair. VisiPlate leverages an ultrathin nanoplate and its insertion procedure reduces operating time and makes follow-up care easier. VisiPlate is made of alumina, an implant material that has been used in hip replacements. Avisi Technologies is headquartered in Philadelphia, Pennsylvania.

Identical

Seed Round in 2020
Identical is a developer of personalized dental implants used to make tooth replacement more accessible and affordable for everyone. Its implants are drill-free and non-invasive and use the latest 3D technology that enables dentists to deliver personalized dental implants in a faster and safer way. It was founded in 2018 and is headquartered in Walnut Creek, California.

Noctrix Health

Funding Round in 2020
Noctrix Health, Inc. develops therapeutic wearable devices to treat chronic neurological and sleep disorders in patients. The company was founded in 2018 and is based in Menlo Park, California.

S2 Genomics

Seed Round in 2019
S2 Genomics, Inc. develops integrated sample preparation systems that processes tissues and liquid samples into genomic samples. The company also provides spatial sequencing technology that captures three dimensional coordinates of single cells in tissue for NGS readout. S2 Genomics, Inc. was founded in 2016 and is based in Livermore, California.

Purissima

Seed Round in 2019
Purissima has developed a unique platform to produce active pharmaceutical ingredient (API) grade molecules through the fermentation of heterotrophic microalgae.

TheraDep

Venture Round in 2018
TheraDep Technologies, Inc. manufactures biologic materials. It offers TheraDep, a technology solution that provides treatment for numerous medical conditions and influences the performance of various medical devices; TherGen, a solution that combines the therapeutic benefits of Cold Atmospheric Plasma (CAP) to apply a layer of collagen; BioDep, medical device coatings that offer coating deposition of biologic materials and drugs for the medical devices, and laboratory analysis equipment and supplies; and BioDep Labware offers a single step dry process to apply biologic materials used in diagnostics and laboratory equipment. The company was founded in 2015 and is based in Palo Alto, California.

InvVax

Venture Round in 2015
InvVax, Inc. develops and commercializes influenza vaccine that prevents pandemics. It focuses on identifying influenza vaccines for HIV, Hepatitis B, and Hepatitis C. The company was founded in 2012 and is based in Los Angeles, California.

Virion Therapeutics

Series A in 2018
Virion Therapeutics, LLC, a biotechnology company, develops immune-based treatments for virally-associated cancers and chronic viral infections. It offers ChiVax and ChiVax-gD vaccines to induce potent and sustained T cell-mediated immune responses against transformed and infected cells. Virion Therapeutics, LLC was incorporated in 2018 and is based in Newark, Delaware.

Physcient

Series A in 2013
Physcient, Inc. manufactures Differential Dissector, a surgical instrument for blunt dissection. Its surgical device is used in plastic surgery and open general surgical procedures, such as thoracic, gastrointestinal, gynecological, urological, peripheral vascular, and orthopedic. The company was founded in 2007 and is based in Durham, North Carolina.

Noctrix Health

Seed Round in 2020
Noctrix Health, Inc. develops therapeutic wearable devices to treat chronic neurological and sleep disorders in patients. The company was founded in 2018 and is based in Menlo Park, California.

Watershed Therapeutics

Seed Round in 2021
Watershed Therapeutics develops a novel, targeted drug-delivery platform for bladder diseases. The initial aim is to stop recurring urinary tract infections. The therapy can be tailored to help patients with overactive bladder, painful bladder syndrome, and bladder cancer.

Carmenta Bioscience

Seed Round in 2013
Carmenta Bioscience is a privately held medical technology company dedicated to improving maternal and fetal health. Spun-out of Stanford University School of Medicine in 2012, Carmenta Bioscience is currently developing a highly accurate, serum-based diagnostic test for preeclampsia.

Embolx

Venture Round in 2017
Embolx is a venture-backed start-up in Silicon Valley developing and commercializing unique catheter-based systems that enable a breakthrough in minimally invasive localized cancer therapy. Embolx devices use pressure regulation to eliminate non-target delivery and increase drug distribution in the tumor using an advanced method known as Low Pressure Embolization (LPE).

Strategikon

Series A in 2021
Strategikon Pharma, Inc. designs and develops a software that synchronizes sponsor and provider outsourcing processes. It offers Clinical Maestro, a transaction room that uses collaborative technology infrastructure and standardized bid grid language to create a shared virtual transaction environment. The company's software is also used for clinical financial management, vendor performance metrics management, portfolio analytics, CRO and clinical vendor oversight, clinical outsourcing, and contract lifecycle management. In addition, it offers consulting services to newly established clinical business operations. Strategikon Pharma, Inc. was founded in 2016 and is based in San Rafael, California.

Seal Rock Therapeutics

Seed Round in 2018
Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.

Chimera Bioengineering

Venture Round in 2019
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia and lymphoma, have shown transformative results for patients unresponsive to standard therapy. However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients. Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w

NuMedii

Series A in 2013
NuMedii is a biotechnology company that discovers and de-risks effective new drugs by translating life sciences big data into therapies. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii. It utilizes hundreds of millions of raw human, biological, pharmacological, and clinical data points. The company was founded in 2008 and headquartered in San Mateo, California.

Ask.Vet

Venture Round in 2016
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.

MoMelan Technologies

Series A in 2011
MoMelan Technologies, Inc. operates as a developer of a device to treat skin disorders by expanding the surface area of skin grafts. The company was incorporated in 2009 and is based in Cambridge, Massachusetts. MoMelan Technologies, Inc. operates as a subsidiary of Acelity L.P. Inc.

Sandstone Diagnostics

Venture Round in 2020
Sandstone Diagnostics offers a centrifuge system that provides plasma and serum collection at-home and the point-of-care. It specializes in the fields of clinical diagnostics, home healthcare, and fertility. It was founded in 2012 and headquartered in Pleasanton, California.

S2 Genomics

Venture Round in 2020
S2 Genomics, Inc. develops integrated sample preparation systems that processes tissues and liquid samples into genomic samples. The company also provides spatial sequencing technology that captures three dimensional coordinates of single cells in tissue for NGS readout. S2 Genomics, Inc. was founded in 2016 and is based in Livermore, California.

Celldom

Venture Round in 2021
Celldom, Inc., a research tools company, develops a single-cell analysis technology to advance research, drug discovery, and development by illuminating diversity in cell populations. Its portfolio includes TrapTx Analyzer System, a technology that integrates phenotypic and genomic data to identify and characterize rare cells that play critical roles in biological pathways and disease. Its platform focuses on developing solutions in the areas of oncology, immunology, and stem cell biology. The company was founded in 2016 and is based in Durham, North Carolina.

Ask.Vet

Seed Round in 2015
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.

Ark.one Health

Venture Round in 2018
Ark.one Health develops a predictive analytics platform for health care systems and plans. The company provides financial performance improvement analytics to health systems as a service.

Allyx Therapeutics

Venture Round in 2021
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies designed to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug that is capable of delivering a disease-modifying approach and preserve cognition in patients.

Satoris

Series B in 2008
Satoris develops tests for neurological diseases such as Alzheimer's, Parkinson's, Multiple Sclerosis, and Diabetic Neuropathy. They're committed to developing and commercializing neurodiagnostic tests that yield the earliest, most accurate, and most clinically relevant diagnoses, so that healthcare costs can be reduced while patient care becomes even more effective.

First Light Diagnostics Inc.

Private Placement in 2019
First Light Diagnostics Inc. develops automated medical diagnostic products for the detection of microbes that cause healthcare/hospital infections. The company offers a benchtop MultiPath analyzer that detects resistant and sensitive Staphylococcus aureus bacteria, toxins, and viruses for hospital clinical microbiology laboratories. It provides its product for various applications, including screening, blood, surgical, skin, and GI infections. The company was formerly known as First Light Biosciences Inc. and changed its name to First Light Diagnostics Inc. in January 2019. First Light Diagnostics Inc. was incorporated in 2006 and is based in Chelmsford, Massachusetts.

Thrive Bioscience

Seed Round in 2015
Thrive Bioscience is commercializing a family of instruments and software that provide imaging, analytics, and automation to significantly improve cell culture and the analysis of live cells. Thrive’s instruments empower biologists to deliver consistent, reproducible results by leveraging microscopy, robotics, fluidics, and other fields, to capture images and data and provide analysis, reports, guidance, documentation, and a database on the cells and on cell culture processes.

First Light Diagnostics

Series A in 2019
First Light Biosciences develops breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare-Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with unprecedented affordability and ease-of-use.

Ask.Vet

Seed Round in 2015
Vet24seven, Inc. introduces Ask.Vet, the online community where veterinarians engage and interact with animal owners to provide trusted, expert advice, information, & resources that help them with the care, health, and well-being of their animals. Ask.Vet was designed as the ‘go-to’ destination for the two hundred million households with animals around the world. Questions are routed to a licensed veterinarian who is trained to educate, direct, and refer the client to a veterinarian, veterinary hospital, or other service providers nearby for diagnosis, treatment, and care. Veterinarians, clinics, and product/service providers will pay a referral free to Ask.Vet for qualified leads.

Allylix

Series C in 2010
Allylix, Inc., an early stage biotechnology company, develops terpene products and their derivatives for the flavor and fragrance, food ingredient, pharmaceutical, agricultural, and biofuel markets. Its products comprise nootkatone, which is a grapefruit flavor that is used in fruit juices and citrus flavored sodas. The company also develops sesquiterpenes that are part of aroma chemical segment of the flavor and fragrance market; and production platforms for pharmaceutical, nutraceutical, and agricultural markets. Allylix, Inc. was founded in 2002 and is based in San Diego, California with research and development laboratories in Lexington, Kentucky.

Avisi Technologies

Seed Round in 2021
Avisi Technologies develops a nanotechnology-enabled defense against blindness from glaucoma. Avisi's product, VisiPlate, is a next-generation aqueous shunt that aims to treat mid to late-stage glaucoma. It is 20x thinner than a human hair. VisiPlate leverages an ultrathin nanoplate and its insertion procedure reduces operating time and makes follow-up care easier. VisiPlate is made of alumina, an implant material that has been used in hip replacements. Avisi Technologies is headquartered in Philadelphia, Pennsylvania.

VALFIX Medical

Venture Round in 2019
VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.

Gemmus Pharma

Series A in 2012
Gemmus Pharma is a drug development company founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.

Niveus Medical

Series A in 2011
Niveus Medical, Inc. provides muscle stimulation systems that provide stimulation to the quadriceps. Its muscle stimulation system is indicated for maintaining or increasing range of motion of the knee joint; and engages in prevention or retardation of disuse atrophy in the quadriceps, muscle re-education of the quadriceps, and relaxation of muscle spasms, as well as increases local blood circulation. The company was founded in 2008 and is based in Redwood City, California.

Mission Bio

Series A in 2017
Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.

Fluxion Biosciences

Series B in 2007
Fluxion Biosciences was formed in 2005 to address critical needs for cellular analysis tools in the pharmaceutical, biotech and research industries. The company has developed a proprietary microfluidic platform which enables precise cellular manipulation, rapid low-volume compound addition, environmental control and software-based data acquisition.

Allyx Therapeutics

Venture Round in 2021
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies designed to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug that is capable of delivering a disease-modifying approach and preserve cognition in patients.

Flyte

Seed Round in 2024
Pelvital is a privately held company that restores Pelvic Health and improve the lives of people. They are currently evaluating the Flyte system, an investigational device designed to strengthen and potentially heal the pelvic floor muscle system, using a unique technology capable of delivering mechanotherapy. It was founded in 2016 and headquartered in Minneapolis, Minnesota.

Averto Medical

Venture Round in 2023
Savage Medical manufactures devices for medical use, enabling patients to get solutions for gastrointestinal diseases. They offer solutions for patients suffering from gastrointestinal diseases.